Baseline and follow-up data
Baseline data included patient demographics and socioeconomic status, patient-reported
data at the time of admission with MI concerning HRQoL (the three-level EuroQol
five-dimension [EQ-5D-3L],Follow-up of HRQoL measured by EQ-5D-3L and EQ-VAS was recorded at 1 month, 6 months, and
12 months. At 10 years, through the EMMACE-XL study (2020–21), the EMMACE cohort
participants were contacted and consented to complete a further quality-of-life
questionnaire (EQ-5D-3L, EQ-VAS), supply their current medication data, and answer a
question relating to their perceived adherence to their current medication as well as to
answer lifestyle questions about their smoking habits. An additional follow-up of the
EMMACE cohort was through the EMMACE- XXL(2021–22) study that collected further
quality-of-life data (EQ-5D-3L, EQ-VAS), information about frailty (using the Program of
Research on Integration of Services for the Maintenance of Autonomy [PRISMA-7] frailty
questionnaire),The EMMACE longitudinal cohort data flow and linkages.